ORIGINAL RESEARCH ARTICLE Long-Term Treatment with Extended-Release Carbidopa– Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial

The Author(s) 2015. This article is published with open access at Springerlink.com Background and Objective IPX066 is a multiparticulate extended-release formulation of carbidopa–levodopa, de-signed to produce prolonged therapeutic levodopa plasma concentrations. This 9-month open-label extension study assessed its long-term safety and clinical utility in early and advanced Parkinson’s disease (PD). Methods Participants were enrolled from two phase III IPX066 studies and one open-label phase II study. Early PD patients were titrated to an appropriate dosing regimen while advanced patients started with regimens established in the antecedent studies. Adjustment was allowed throughout the extension. Clinical utility measures in-cluded the Unified Parkinson’s Disease Rating Scal